Multiple system atrophy (MSA) frequently involves autonomic dysfunction that manifests as overactive bladder (OAB). Affected patients present with urinary frequency, urinary urgency, and urinary urge incontinence — symptoms that may prove difficult to control and require a structured, evidence-based approach.
In patients with MSA, the triad of urinary frequency, urinary urgency, and urinary urge incontinence reflects underlying detrusor dysfunction. These symptoms can persist or become refractory, warranting escalation beyond standard first-line measures and careful evaluation of the underlying bladder behaviour.
For cases of refractory detrusor overactivity in MSA, a bladder-directed injection procedure has been studied and shown benefit in clinical investigation. The complete evidence-based regimen — including patient selection, procedural approach, and full decision algorithm — is available in the structured protocol below.
Full protocol details available via the link below ↓Overactive bladder symptoms of urinary frequency, urgency, and urge incontinence can be managed by using selective β3-adrenergic receptors (such as mirabegron 25 mg 1 time a day titrating to 50 mg 1 time a day if needed or vibegron 75 mg 1 time a day), which have no anticholinergic side effects but may cause hypertension, abdominal pain, and urinary retention.
Botulinum toxin injections into the bladder ameliorated refractory detrusor overactivity in an open-label study in patients with Parkinson disease and multiple system atrophy.
View source ↗